Vivacelle Bio

Vivacelle Bio is a private, late-stage biotech company targeting the urgent global crisis of sepsis and hypovolemic shock with its innovative phospholipid nanoparticle platform. The company's lead asset, VBI-S, has demonstrated 100% efficacy in a Phase II trial for elevating blood pressure in septic shock patients refractory to standard therapy and is now enrolling a Phase III study. Backed by venture capital, the U.S. Department of Defense, and the National Institutes of Health, Vivacelle aims to transform critical care outcomes by addressing a profound unmet medical need with a potentially first-in-class mechanism.

Patented phospholipid nanoparticle technology designed to restore intravascular volume and selectively redistribute excess nitric oxide to reverse hypotension in hypovolemic shock.

The competitive landscape for septic shock is characterized by a decades-old standard of care (fluids and vasopressors) with high mortality, indicating a clear gap. While other companies are exploring immunomodulators and supportive therapies, Vivacelle's nitric oxide redistribution mechanism appears novel and directly targets refractory hypotension, a key driver of mortality, potentially giving it a differentiated profile.